-
Accept this holiday gift!
Time of Update: 2021-06-08
On May 31, the Center for Drug Evaluation (CDE) of the National Medical Products Administration announced the opening of the "Children's Drug Column" on June 1, and will centrally disclose policies, regulations, guidelines, and training materials related to children's drug use.
-
U.S. FDA Approval of Listed Drugs and my country's Domestic Application Status in the First Quarter of 2021
Time of Update: 2021-06-08
There are 4 new drug applications for Type 3 NMD, among which MYRBETRIQ GRANULES has been approved through the priority review channel, pemetrexed has the same variety of domestic products listed in my country, and 20 domestic enterprises of the same variety have been approved.
-
Start inspections in multiple places and start inspections in these hospitals (list attached)
Time of Update: 2021-06-08
Cut the chain of medicine corruption, and make purchases with a large amount to become an anti-corruption tool On April 27, the Medical Administration and Hospital Administration of the National Health Commission announced in the "Notice on Issuing the Main Points of Correction of Unhealthy Practices in the Field of Pharmaceutical Purchase and Sales and Medical Services in 2021 ", announcing a new round of work to correct unhealthy practices in the field of medicine.
-
Original non-viral oncolytic IO drug
Time of Update: 2021-06-08
At present, there are several underlying issues in this field that need to be resolved, such as which local immune indicators can predict systemic efficacy, which type of lesion is suitable for administration for patients with metastases, which stage of the tumor is suitable for oncolytic drugs (late metastasis or early preoperative), and clinical End point, optimal dose (maximum tolerated dose MTD or optimal biological dose BOD), etc.
-
News of the adjustment of the list of essential medicines came out
Time of Update: 2021-06-08
comIn September of this year, the three-year basic drug catalogue adjustment may begin, and companies can seize this opportunity to increase the volume of new products.
-
Domestic pharmaceutical companies are investing in R&D: Hengrui, Beida, Junshi...
Time of Update: 2021-06-08
Picture of R&D investment of Chinese A-share listed pharmaceutical companies Data source: Wind, Zhongkang Industrial Capital Research Center Leading innovative pharmaceutical companies take a multi-pronged approach to enhance R&D strength At present, some domestic A-share listed innovative drug companies, such as Hengrui Pharmaceuticals, Betta Pharmaceuticals, Junshi Biology, and Chipset Biology, are strengthening their R&D capabilities from multiple dimensions such as R&D expenditures, attracting talents , and optimizing incentive mechanisms.
-
Guangdong pharmacies, the sale of these 37 drugs must be registered with real names!
Time of Update: 2021-06-08
Previously, the Zhongshan City Market Supervision Bureau found many times during inspections that some retail pharmacies did not strictly implement the information registration and report system for selling fever drugs, daily cleaning and disinfection , door-to-door temperature measurement and code scanning, employees’ daily health monitoring reports and other personnel prevention and control measures The implementation is not in place.
-
Another batch of pharmacies don’t need licensed pharmacists for the time being
Time of Update: 2021-06-08
In addition, the "Notice" also mentioned that pharmaceutical retail chain stores are equipped with licensed pharmacists or legally qualified pharmaceutical technicians in accordance with regulations, encouraging and supporting pharmaceutical retail chain companies to use modern information technology to carry out remote prescription audits, as its basis The store’s prescription review and supplementation of pharmacy services have solved the problem that the store’s licensed pharmacists cannot sell prescription drugs temporarily when they are absent.
-
How should the drug manufacturer on the docking list receive drug inspections?
Time of Update: 2021-06-08
2. Refuse and evade supervision and inspectionIf there is evidence that a drug manufacturer may have a potential safety hazard, the drug supervision and administration department shall, based on the supervision and inspection situation, take measures such as warnings, interviews, rectification within a time limit, and suspension of production, sales, use, and import, and promptly announce the inspection and handling results.
-
Hengrui Medicine's "Azilsartan Tablets" will be approved soon
Time of Update: 2021-06-05
On May 31, the Insight intelligence monitoring system showed that the listing application of Hengrui's 3 generic drug "Azilsartan Tablets" was "under review" (acceptance number: CYHS1700171, CYHS1700170), and two rounds of supplementary information were passed through the review process And the clinical trial on-site verification is expected to be approved soon.
-
The top five brands in the retail market of rhinitis drugs are stable and foreign capital still dominates
Time of Update: 2021-06-05
Figure 4: 2016-2020 trend of changes in the share of the top five brands of rhinitis drugs in the three cities In the rhinitis drug market in the three cities of Nanjing, Qingdao and Wuhan, chemical drugs are leading the market and are singing all the way.
-
"Several Opinions": Shanghai may set off a "wave" of supporting policies for the development of the biomedical industry
Time of Update: 2021-06-05
Table 1: Pictures of Shanghai Municipal Biomedical Industry Policy DocumentsSource: According to public informationFrom the perspective of policy support, the "Several Opinions" are at the forefront of the country in terms of improving the ability of innovative sources, strengthening the research and development of innovative products, and accelerating the application of innovative products.
-
Don’t endure cancer pain. The earlier you use painkillers, the better
Time of Update: 2021-06-05
He said that with the advancement of anti-tumor treatment drug technology and the improvement of treatment plans, the quality of life of cancer patients should also receive more attention.
-
Ipsen RARγ agonist palovarotene enters priority review in the U.S. and Europe
Time of Update: 2021-06-05
S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) of palovarotene and granted priority review, which is used to treat progressive ossificans fibrotic dysplasia (FOP, also known as "Stone Man Syndrome").
-
The CEO of Janssen Pharmaceuticals Korea is confirmed!
Time of Update: 2021-06-05
From 2011 to 2015, he served as the head of finance of Xi'an Janssen, and later served as the senior financial director of Johnson & Johnson in Southeast Asia and the chief of the Asia Pacific region of Janssen Finance officer.
-
Yingli Pharmaceutical's PI3Kδ inhibitor has obtained three FDA orphan drug qualifications
Time of Update: 2021-06-05
Article source: Pharmaceutical GuanlanOn May 28, Yingli Pharmaceuticals announced that the US FDA officially granted its PI3Kδ inhibitor linpris tablets (YY-20394) a new orphan drug designation for the treatment of patients with T-cell lymphoma.
-
The State Food and Drug Administration issued an announcement on updating the list of banned ingredients for cosmetics
Time of Update: 2021-06-05
On the 28th, the State Food and Drug Administration organized a review of the "Prohibited Components of Cosmetics (Table 1)" and "Prohibited Plant (Animal) Components of Cosmetics (Table 2)" in Chapter 2 of the "Safety Technical Specifications for Cosmetics (2015 Edition)".
-
865 million yuan annual salary!
Time of Update: 2021-06-05
In general, CEOs of companies involved in the development of new crown vaccines and drugs will receive higher salaries, such as Regeneron and Novavacs.
58 million US dollarsAlthough Johnson & Johnson failed to achieve sales and adjusted earnings targets, the company's CEO Alex Gorsky still achieved a 17% salary increase in 2020.
-
A line of squamous NSCLC!
Time of Update: 2021-06-05
The ORIENT-12 study is a randomized, double-blind, phase III controlled clinical study evaluating the effectiveness and safety of sintilimab or placebo combined with gemcitabine and platinum for the first-line treatment of advanced or metastatic squamous NSCLC (NCT03629925 ), a total of 57 subjects were enrolled.
-
Improved innovation creates the next golden track for pharmaceutical companies
Time of Update: 2021-06-05
531 ，，。，，，。 “”，。。，、、，。，、。 “”“” 。，，10。，。 ，505b（2），505（b）22。，，——“”“”。 ，“”，，。，。，，；，，；。，。 ，，“”。，，“”“”。，，“”，。 ，。 ，2015，，40。，1，10。，me bet t er。，，。 ，Al ker mes。Al ker mes，2015。2018。621，。 。2017，。，，，。。 ，。，，，。，。，（）。 ，，。，“”，。 ，、。，，，。，。 531 ，，。，，，。 “”，。。，、、，。，、。 “”“” 。，，10。，。 ，505b（2），505（b）22。，，——“”“”。 In addition to increasing indications, most of the "reforms" are based on pharmaceutical research, that is, using various mature or iterative new pharmaceutical technologies and even medical device technologies to further improve compounds that have been clinically verified.
